Another TXNRD1-inhibitor, arsenic trioxide, was tested as local interstitial monotherapy in a single-arm, phase I/II GBM trial with the first promising results [68], outperformed alkylating AntiBCs in vivo and in vitro and an ABC transporter inhibitor. This evidence concerns the gene TXNRD1 and glioblastoma.